Toxoplasma gondii parasite uses unconventional method to make proteins for evasion of drug treatment
A study by Indiana University School of Medicine researchers sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment. It was recently .
Toxoplasma gondii is a single-celled parasite that people catch from cat feces, unwashed produce or undercooked meat. The parasite has infected up to one-third of the world's population, and after causing mild illness, it persists by entering a dormant phase housed in cysts throughout the body, including the brain.

Toxoplasma cysts have been linked to behavior changes and neurological disorders like schizophrenia. They can also reactivate when the immune system is weakened, causing life-threatening organ damage. While drugs are available to put toxoplasmosis into remission, there is no way to clear the infection. A better understanding of how the parasite develops into cysts would help scientists find a cure.
Through years of collaborative work, IU School of Medicine professors , and , have shown that Toxoplasma forms cysts by altering which proteins are made. Proteins govern the fate of cells and are encoded by mRNAs.
"But mRNAs can be present in cells without being made into protein," Sullivan said. "We've shown that Toxoplasma switches which mRNAs are made into protein when converting into cysts."
Lead author , a postdoctoral fellow at the IU School of Medicine and a member of , examined the so-called leader sequences of genes named BFD1 and BFD2, both of which are necessary for Toxoplasma to form cysts.
"mRNAs not only encode for protein, but they begin with a leader sequence that contains information on when that mRNA should be made into protein," Dey said.
All mRNAs have a structure called a cap at the beginning of their leader sequence. Ribosomes, which convert mRNA into protein, bind to the cap and scan the leader until it finds the right code to begin making the protein.
"What we found was that, during cyst formation, BFD2 is made into protein after ribosomes bind the cap and scan the leader, as expected," Dey said. "But BFD1 does not follow that convention. Its production does not rely on the mRNA cap like most other mRNAs."
The team further showed that BFD1 is made into protein only after BFD2 binds specific sites in the BFD1 mRNA leader sequence.
Sullivan said this is a phenomenon called cap-independent translation, which is more commonly seen in viruses.
"Finding it in a microbe that has cellular anatomy like our own was surprising," Sullivan said. "It speaks to how old this system of protein production is in cellular evolution. We're also excited because the players involved do not exist in human cells, which makes them good potential drug targets."
The Journal of Biological Chemistry featured the new study as an Editor's Pick, which represent a select group of the journal’s publications judged to be of exceptionally high quality and broad general interest to their readership.
This article is republished from the . Read the original .
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Scientists identify pan-cancer biomarkers
Researchers analyze protein and RNA data across 13 cancer types to find similarities that could improve cancer staging, prognosis and treatment strategies. Read about this recent article published in Molecular & Cellular Proteomics.

New mass spectrometry tool accurately identifies bacteria
Scientists develop a software tool to categorize microbe species and antibiotic resistance markers to aid clinical and environmental research. Read about this recent article published in Molecular & Cellular Proteomics.

New tool matches microbial and metabolic metaproteomic data
Scientists develop a bioinformatics program that maps omics data to metabolic pathways. Read about this recent article published in Molecular & Cellular Proteomics

Meet Paul Shapiro
Learn how the JBC associate editor went from milking cows on a dairy farm to analyzing kinases in the lab.

CRISPR epigenome editor offers potential gene therapies
Scientists from the University of California, Berkeley, created a system to modify the methylation patterns in neurons. They presented their findings at ASBMB 2025.

Finding a symphony among complex molecules
MOSAIC scholar Stanna Dorn uses total synthesis to recreate rare bacterial natural products with potential therapeutic applications.